Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1012 participants.

Also called NCT01176968

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,012 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01176968
  • EudraCT 2010-019844-38
Other papers using this trial's data
  • Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study European heart journal, 2014-09-07 DOI, PubMed 24780614

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada, Czechia, France, Germany, Greece, Hungary, Netherlands, Poland, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01176968. Randomized; quadruple masking; primary purpose prevention. Start 2010-09 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2016-08-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
Acronym
REMINDER
Intervention (Drug)
Eplerenone
Intervention (Drug)
Placebo
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (class: industry)

Record details

Record id
cardio:ct-nct01176968
Content hash
a18837bc7b4e16084544f0534a830b64498dd50393b41fc2b22b99f78bc074e9